Economics of corneal cross-linking for keratoconus treatment
After modeling a conservative cost of corneal transplantation and incorporating an age-dependent disease progression rate, our evaluation confirmed that CXL was the dominant (i.e. cost-saving and cost-effective) treatment strategy, primarily due to greatly improved patient outcomes (i.e. benefits strongly correlated with visual acuity). As novel and less invasive methods (e.g. transepithelial CXL) enter the market, it is expected that the demand for corneal cross-linking will increase given its significant clinical and economic value.
Authors
- John P. Berdahl (ORCID: https://orcid.org/0000-0002-5468-7405)
- Christopher J. Rapuano
- Richard L. Lindstrom (ORCID: https://orcid.org/0000-0002-7935-9512)
- John A. Carter (ORCID: https://orcid.org/0000-0001-8539-5352)
- Vance Thompson (ORCID: https://orcid.org/0000-0003-2198-841X)
- Eric D. Donnenfeld (ORCID: https://orcid.org/0000-0002-5235-1780)
- David Kratochvil
Institutions
- University of South Dakota (US)
- The Open Group (GB)
- Vance Thompson Vision (US)
- H.B. Fuller (United States) (US)
- Minnesota Eye Consultants (US)
- Federal State Scientific Institution Research Institute of Eye Diseases (RU)
- New York University (US)
- Wills Eye Hospital (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1080/13696998.2025.2564576
- Citations
- 3
- Primary Topic
- Corneal surgery and disorders
- Type
- article
- Field-Weighted Citation Impact
- 4.08